Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) dropped 1.4% on Friday . The company traded as low as $13.74 and last traded at $13.85, with a volume of 72,556 shares traded. The stock had previously closed at $14.04.

RVNC has been the subject of a number of recent research reports. Brean Capital restated a “buy” rating and issued a $48.00 target price on shares of Revance Therapeutics in a research report on Tuesday, May 24th. Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Guggenheim reiterated a “buy” rating and issued a $55.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, June 14th. SunTrust Banks Inc. lowered their price objective on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, June 14th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $35.00 price objective (down previously from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $39.60.

The firm’s market capitalization is $394.50 million. The stock has a 50 day moving average of $14.16 and a 200-day moving average of $16.57.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by $0.02. The company earned $0.80 million during the quarter, compared to analysts’ expectations of $0.06 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities analysts forecast that Revance Therapeutics Inc. will post ($3.53) EPS for the current fiscal year.

An institutional investor recently bought a new position in Revance Therapeutics stock. Ameriprise Financial Inc. bought a new stake in Revance Therapeutics Inc. (NASDAQ:RVNC) during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 41,957 shares of the biopharmaceutical company’s stock, valued at approximately $1,433,000. Ameriprise Financial Inc. owned 0.15% of Revance Therapeutics as of its most recent filing with the SEC.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.